Hyaluronidase

Generic Name: Hyaluronidase

Brand Names: Amphadase

Drug Type: Biotech

CAS Number: 9001-54-1

Unique Ingredient Identifier: 8KOG53Z5EM

Background: Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.

Hyaluronidase was first used in prescription products in the United States on 5 May 2004.

Indication: Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.

Associated Therapies: Parenteral rehydration therapy, Parenteral drug administration, Subcutaneous urography

Clinical Trials

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Polatuzumab vedotin (PV)
Drug: Rituximab
Drug: Hyaluronidase
Drug: Gemcitabine
Drug: Cisplatin
Drug: Dexamethasone
Drug: GCSF

First Posted Date: 2022-08-11

Last Posted Date: 2025-03-05

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 44

Registration Number: NCT05498220

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Comparison of Hyaluronidase and Dexametasone in Reduction of Postoperative Edema

Phase 4

Completed

Conditions: Edema
Trismus
Infection, Surgical Site
Pain

Interventions: Drug: Hyaluronidase Injection mesomedica
Drug: Dexamethasone dekort

First Posted Date: 2022-07-20

Last Posted Date: 2022-07-20

Lead Sponsor: Hacettepe University

Target Recruit Count: 60

Registration Number: NCT05466604

Locations: 🇨🇾
Near East University, Nicosia, Cyprus
🇹🇷
Hacettepe University, Ankara, Sıhhiye, Turkey

Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer

Phase 1

Completed

Conditions: Health, Subjective

Interventions: Drug: ALT-BB4
Drug: 0.9%NaCl

First Posted Date: 2022-02-09

Last Posted Date: 2022-12-13

Lead Sponsor: Alteogen, Inc.

Target Recruit Count: 290

Registration Number: NCT05232175

Locations: 🇰🇷
Research Site, Seoul, Korea, Republic of

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Phase 1

Withdrawn

Conditions: Relapsed Hematologic Malignancy
Refractory Hematologic Malignancy

Interventions: Drug: Tazemetostat
Drug: Daratumumab (Intravenously)
Drug: Tafasitamab
Drug: Acalabrutinib
Drug: Mosunetuzumab
Drug: Lenalidomide
Drug: Daratumumab (Subcutaneously)
Drug: Hyaluronidase-Fihj
Drug: Pomalidomide
Drug: Dexamethasone 20mg

First Posted Date: 2022-01-25

Last Posted Date: 2023-08-15

Lead Sponsor: Epizyme, Inc.

Registration Number: NCT05205252

Locations: 🇺🇸
Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸
California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
🇺🇸
Astera Cancer Center, East Brunswick, New Jersey, United States

Effectiveness of Adding Hyaluronidase to Bupivacaine in Ultrasound Guided Supraclavicular Brachial Plexus Block

Phase 2

Conditions: Postoperative Pain

Interventions: Drug: Hyaluronidase

First Posted Date: 2021-10-19

Last Posted Date: 2021-10-27

Lead Sponsor: Sohag University

Target Recruit Count: 40

Registration Number: NCT05083663

Locations: 🇪🇬
Sohag University Hospital, Sohag, Egypt

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer
Breast Neoplasm
Breast Cancer Invasive
Breast Cancer Female
Breast Cancer Stage II
Breast Cancer Stage III
Hormone Receptor-positive Breast Cancer
HER2-positive Breast Cancer
Triple Negative Breast Neoplasms
Estrogen Receptor-positive Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Doxorubicin
Drug: Carboplatin
Drug: Trastuzumab
Drug: Pertuzumab
Drug: Cyclophosphamide
Drug: Pembrolizumab
Drug: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf

First Posted Date: 2021-08-25

Last Posted Date: 2025-02-27

Lead Sponsor: Baylor Breast Care Center

Target Recruit Count: 185

Registration Number: NCT05020860

Locations: 🇺🇸
Harris Health System - Smith Clinic, Houston, Texas, United States
🇺🇸
O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States